Lonza Group AG

SWX:LONN Stock Report

Market Cap: CHF 38.6b

Lonza Group Valuation

Is LONN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LONN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LONN (CHF534.6) is trading above our estimate of fair value (CHF348.67)

Significantly Below Fair Value: LONN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LONN?

Other financial metrics that can be useful for relative valuation.

LONN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6x
Enterprise Value/EBITDA22x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does LONN's PE Ratio compare to its peers?

The above table shows the PE ratio for LONN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.9x
BANB Bachem Holding
47x18.7%CHF 5.3b
SFZN Siegfried Holding
37.9x13.6%CHF 4.9b
TECN Tecan Group
35.2x15.6%CHF 3.6b
SKAN SKAN Group
55.6x18.7%CHF 1.8b
LONN Lonza Group
67.4x24.7%CHF 38.6b

Price-To-Earnings vs Peers: LONN is expensive based on its Price-To-Earnings Ratio (67.4x) compared to the peer average (43.9x).

Price to Earnings Ratio vs Industry

How does LONN's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: LONN is expensive based on its Price-To-Earnings Ratio (67.4x) compared to the European Life Sciences industry average (48.1x).

Price to Earnings Ratio vs Fair Ratio

What is LONN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LONN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio67.4x
Fair PE Ratio39.1x

Price-To-Earnings vs Fair Ratio: LONN is expensive based on its Price-To-Earnings Ratio (67.4x) compared to the estimated Fair Price-To-Earnings Ratio (39.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LONN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 534.60
CHF 624.14
+16.7%
6.4%CHF 700.00CHF 530.00n/a21
Sep ’25CHF 555.60
CHF 619.41
+11.5%
7.0%CHF 700.00CHF 530.00n/a22
Aug ’25CHF 587.40
CHF 613.55
+4.5%
8.0%CHF 700.00CHF 495.00n/a22
Jul ’25CHF 488.40
CHF 586.00
+20.0%
9.4%CHF 666.00CHF 450.00n/a22
Jun ’25CHF 486.40
CHF 576.86
+18.6%
12.1%CHF 655.00CHF 375.00n/a22
May ’25CHF 510.40
CHF 566.00
+10.9%
12.1%CHF 650.00CHF 375.00n/a22
Apr ’25CHF 540.20
CHF 556.00
+2.9%
12.8%CHF 650.00CHF 375.00n/a22
Mar ’25CHF 465.60
CHF 508.25
+9.2%
13.3%CHF 635.00CHF 365.00n/a20
Feb ’25CHF 427.70
CHF 495.20
+15.8%
14.0%CHF 600.00CHF 365.00n/a20
Jan ’25CHF 353.70
CHF 465.16
+31.5%
18.5%CHF 600.00CHF 270.00n/a19
Dec ’24CHF 334.80
CHF 513.11
+53.3%
21.9%CHF 705.00CHF 365.00n/a19
Nov ’24CHF 318.60
CHF 531.26
+66.7%
20.8%CHF 705.00CHF 365.00n/a19
Oct ’24CHF 425.60
CHF 627.41
+47.4%
8.5%CHF 705.00CHF 514.00CHF 534.6017
Sep ’24CHF 492.50
CHF 629.83
+27.9%
7.3%CHF 705.00CHF 530.00CHF 555.6018
Aug ’24CHF 505.20
CHF 647.06
+28.1%
6.9%CHF 705.00CHF 570.00CHF 587.4018
Jul ’24CHF 533.40
CHF 679.24
+27.3%
11.1%CHF 900.00CHF 580.00CHF 488.4017
Jun ’24CHF 575.80
CHF 659.84
+14.6%
16.9%CHF 900.00CHF 315.05CHF 486.4018
May ’24CHF 553.80
CHF 663.36
+19.8%
17.1%CHF 900.00CHF 315.05CHF 510.4017
Apr ’24CHF 547.40
CHF 662.77
+21.1%
17.1%CHF 900.00CHF 315.05CHF 540.2017
Mar ’24CHF 559.60
CHF 662.89
+18.5%
16.6%CHF 900.00CHF 315.05CHF 465.6018
Feb ’24CHF 521.00
CHF 659.65
+26.6%
18.0%CHF 935.00CHF 315.05CHF 427.7017
Jan ’24CHF 453.10
CHF 680.88
+50.3%
19.4%CHF 965.00CHF 315.05CHF 353.7016
Dec ’23CHF 509.00
CHF 699.00
+37.3%
17.8%CHF 965.00CHF 315.05CHF 334.8016
Nov ’23CHF 489.00
CHF 709.06
+45.0%
18.2%CHF 965.00CHF 315.05CHF 318.6017
Oct ’23CHF 486.30
CHF 718.38
+47.7%
18.6%CHF 965.00CHF 315.05CHF 425.6016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y